Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Long-term Investments
Investments the company intends to hold for more than a year.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Long-term Investments · Q1 FY2026 · quarter ended Mar 2026
Long-term investments falls 27.0% from a year ago
Long-term investments stood at $1.34M at the end of Q1 FY2026, down 27.0% from a year earlier and down 92.2% from the prior quarter.
Context
- Long-term investments amounted to 0.2% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term investments keeps falling in the next quarterly balance sheet after a -27.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 17.27M USD
- Year-over-year change
- —
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.27M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Investments vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 long-term investments of $1.34M is the 3rd highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of -27.0% is the 2nd highest of 4, against a peer median of -31.9%.
- Long-term investments amounts to 0.2% of total assets for ZBIO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $85.37M | +0.2% | +70.4% | 43.0% | |
| Dec 2025 | $2.44M | -31.9% | +10.6% | 21.3% | |
| Mar 2026 | $1.34M | -27.0% | — | 0.2% | |
| Sep 2026 | $0 | — | — | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -70.7% | 0.0% | |
UPBUpstream Bio, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding ZBIO) | $0 | -31.9% | +10.6% | 0.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.